Active ingredientGadopiclenolCat. No. P-G006-001CAS 933983-75-6Family · Pharmaceutical analytical standards
Gadopiclenol
A macrocyclic gadolinium-based contrast agent for magnetic resonance imaging, developed in France and approved in the United States in 2022 and in the European Union in 2023. This family brings together the active ingredient and other impurities.
Did you know?Its relaxivity is very high, partly because its gadolinium atom binds two water molecules rather than the single one found in most gadolinium-based contrast agents.
Go to the active ingredient →Active ingredientGadopiclenolCat. No. P-G006-001CAS 933983-75-6
ImpurityGadopiclenol Impurity 1Cat. No. P-G006-002CAS 933983-88-1
ImpurityGadopiclenol Impurity 2Cat. No. P-G006-003CAS 311772-46-0
ImpurityGadopiclenol Impurity 3Cat. No. P-G006-004CAS 2410182-15-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.